Patients who do not respond to current rheumatoid arthritis (RA) treatments may benefit from a new form of treatment that has been shown in a study to be effective against symptoms of the disease.
The RA-BEAM study is the first to demonstrate that the drug baricitinib is more effective in improving the symptoms of rheumatoid arthritis than the current standard treatment of injectable biologic anti-TNF medications. Baricitinib has been specifically developed as a treatment for rheumatoid arthritis.
A common and potentially debilitating disease, rheumatoid arthritis typically affects multiple joints and causes pain, swelling and stiffness that can greatly affect a person’s quality of life.